Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Total Valuation
Haemonetics has a market cap or net worth of $2.68B. The enterprise value is $3.57B.
Market Cap$2.68B
Enterprise Value$3.57B
Share Statistics
Haemonetics has 46,471,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,471,350
Owned by Insiders1.39%
Owned by Institutions11.56%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 8.06%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)8.06%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee372.11K
Profits Per Employee45.85K
Employee Count3,657
Asset Turnover0.56
Inventory Turnover1.59
Valuation Ratios
The current PE Ratio of Haemonetics is 15.9. Haemonetics’s PEG ratio is 0.44.
PE Ratio15.9
PS Ratio2.34
PB Ratio3.87
Price to Fair Value3.87
Price to FCF22.33
Price to Operating Cash Flow7.98
PEG Ratio0.44
Income Statement
In the last 12 months, Haemonetics had revenue of 1.36B and earned 167.68M in profits. Earnings per share was 3.31.
Revenue1.36B
Gross Profit778.55M
Operating Income221.82M
Pretax Income212.07M
Net Income167.68M
EBITDA355.99M
Earnings Per Share (EPS)3.31
Cash Flow
In the last 12 months, operating cash flow was 338.84M and capital expenditures -30.76M, giving a free cash flow of 308.07M billion.
Operating Cash Flow338.84M
Free Cash Flow308.07M
Free Cash Flow per Share6.63
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change-9.88%
50-Day Moving Average74.77
200-Day Moving Average66.32
Relative Strength Index (RSI)22.97
Average Volume (3m)949.51K
Important Dates
Haemonetics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 5, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 1.62, with Debt / Equity ratio of 134.37%
Current Ratio1.62
Quick Ratio0.99
Debt to Market Cap0.39
Net Debt to EBITDA2.58
Interest Coverage Ratio22.76
Taxes
In the past 12 months, Haemonetics has paid 44.39M in taxes.
Income Tax44.39M
Effective Tax Rate0.21
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 11.51, with an EV/FCF ratio of 28.77.
EV to Sales3.01
EV to EBITDA11.51
EV to Free Cash Flow28.77
EV to Operating Cash Flow22.55
Balance Sheet
Haemonetics has $363.37M in cash and marketable securities with $1.22B in debt, giving a net cash position of -$861.37M billion.
Cash & Marketable Securities$363.37M
Total Debt$1.22B
Net Cash-$861.37M
Net Cash Per Share-$18.54
Tangible Book Value Per Share-$4.75
Margins
Gross margin is 58.49%, with operating margin of 16.30%, and net profit margin of 12.32%.
Gross Margin58.49%
Operating Margin16.30%
Pretax Margin15.58%
Net Profit Margin12.32%
EBITDA Margin26.16%
EBIT Margin18.16%
Analyst Forecast
The average price target for Haemonetics is $83.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$83.14
Price Target Upside43.94% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast-2.45%
EPS Growth Forecast41.50%